Exicure Inc. (XCUR) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Exicure Inc. (XCUR)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

9.11

0.49 (5.68%)

At close: Jan 15, 2025, 3:59 PM

9.14

0.33%

After-hours Jan 15, 2025, 04:00 PM EST

undefined% (undefined)

Bid	8.75
Market Cap	23.74M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-2.02
PE Ratio (ttm)	-4.51
Forward PE	n/a
Analyst	n/a

Ask	13
Volume	124,902
Avg. Volume (20D)	730,826
Open	9.90
Previous Close	8.62
Day's Range	9.03 - 11.37
52-Week Range	1.44 - 36.00
Beta	undefined

About XCUR

Exicure, Inc., a biotechnology company, develops therapies for neurological disorders and hair loss based on its proprietary spherical nucleic acid (SNA) technology. Its lead program candidate includes SCN9A that is in preclinical studies for neuropathic and chronic pain. The company has a collaboration, option, and license agreement with AbbVie Inc. to develop SNA-based treatments for hair loss disorders; and collaboration agreement with Ipsen S...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date May 22, 2018

Employees 5

Stock Exchange NASDAQ

Ticker Symbol XCUR

Website https://www.exicuretx.com

Why Price Moved

1 month ago · Source

+35.86%

Exicure shares are trading higher after the compan... Unlock content with Pro Subscription

3 months ago · Source

+3.62%

Exicure shares are trading higher after the company announced it received an extension from the Nasdaq Hearings Panel.

News

2 weeks ago · businesswire.com

Exicure, Inc. Partners with GPCR Therapeutics to Fuel New Growth in Biotech

CHICAGO--(BUSINESS WIRE)--Exicure, Inc. Partners with GPCR Therapeutics Inc. to Fuel New Growth in Biotech.

3 weeks ago · businesswire.com

CORRECTING and REPLACING Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes

CHICAGO--(BUSINESS WIRE)--Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes.

3 weeks ago · businesswire.com

Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes

CHICAGO--(BUSINESS WIRE)--Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes.

2 months ago · businesswire.com

Exicure, Inc. Enters into Purchase Agreements for $1.3 Million and $8.7 Million Equity Financing and Reports Third Quarter 2024 Financial Results

CHICAGO--(BUSINESS WIRE)--Exicure, Inc. Enters into Purchase Agreements for $1.3 Million and $8.7 Million Equity Financing and Reports Third Quarter 2024 Financial Results.